Stock Scorecard
Stock Summary for Pacira BioSciences Inc (PCRX) - $22.93 as of 1/12/2026 8:46:44 PM EST
Total Score
10 out of 30
Safety Score
40 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for PCRX
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for PCRX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for PCRX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for PCRX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for PCRX (40 out of 100)
| Stock Price Rating (Max of 10) | 7 |
| Historical Stock Price Rating (Max of 10) | 8 |
| Stock Price Trend (Max of 10) | 2 |
| Book Value (Max of 10) | 6 |
| Book Value to Price (Max of 10) | 1 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 2 |
| Trading Volume (Max of 10) | 6 |
| Price to Earnings (Max of 10) | 2 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Financial Details for PCRX
Company Overview |
|
|---|---|
| Ticker | PCRX |
| Company Name | Pacira BioSciences Inc |
| Country | USA |
| Description | Pacira BioSciences, Inc. (PCRX) is a leading biopharmaceutical company based in Parsippany, New Jersey, focused on revolutionizing pain management through its innovative non-opioid therapies and regenerative health solutions. By providing advanced alternatives to traditional opioid treatments, Pacira aims to significantly reduce opioid dependence while enhancing patient outcomes and supporting healthcare practitioners. With a promising pipeline and a steadfast commitment to research and development, the company is poised to play a crucial role in the future of pain management, driving both clinical advancements and overall improvements in patient care within the healthcare landscape. |
| Sector Name | HEALTHCARE |
| Industry Name | DRUG MANUFACTURERS - SPECIALTY & GENERIC |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 22.93 |
| Price 4 Years Ago | 38.61 |
| Last Day Price Updated | 1/12/2026 8:46:44 PM EST |
| Last Day Volume | 665,708 |
| Average Daily Volume | 866,368 |
| 52-Week High | 27.64 |
| 52-Week Low | 19.84 |
| Last Price to 52 Week Low | 15.57% |
Valuation Measures |
|
| Trailing PE | 50.06 |
| Industry PE | 114.75 |
| Sector PE | 123.98 |
| 5-Year Average PE | 14.77 |
| Free Cash Flow Ratio | 6.39 |
| Industry Free Cash Flow Ratio | 12.83 |
| Sector Free Cash Flow Ratio | 29.04 |
| Current Ratio Most Recent Quarter | 5.26 |
| Total Cash Per Share | 3.59 |
| Book Value Per Share Most Recent Quarter | 16.93 |
| Price to Book Ratio | 1.54 |
| Industry Price to Book Ratio | 19.42 |
| Sector Price to Book Ratio | 24.69 |
| Price to Sales Ratio Twelve Trailing Months | 1.41 |
| Industry Price to Sales Ratio Twelve Trailing Months | 3.19 |
| Sector Price to Sales Ratio Twelve Trailing Months | 19.33 |
| Analyst Buy Ratings | 3 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 41,100,000 |
| Market Capitalization | 942,423,000 |
| Institutional Ownership | 113.96% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | -47.80% |
| Annual Earnings Growth | -337.30% |
| Reported EPS 12 Trailing Months | 0.47 |
| Reported EPS Past Year | 1.21 |
| Reported EPS Prior Year | 3.21 |
| Net Income Twelve Trailing Months | 21,438,000 |
| Net Income Past Year | -99,560,000 |
| Net Income Prior Year | 41,955,000 |
| Quarterly Revenue Growth YOY | 6.50% |
| 5-Year Revenue Growth | 10.73% |
| Operating Margin Twelve Trailing Months | 7.33% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 147,589,000 |
| Total Cash Past Year | 276,774,000 |
| Total Cash Prior Year | 153,298,000 |
| Net Cash Position Most Recent Quarter | -229,132,000 |
| Net Cash Position Past Year | -106,771,000 |
| Long Term Debt Past Year | 383,545,000 |
| Long Term Debt Prior Year | 513,796,000 |
| Total Debt Most Recent Quarter | 376,721,000 |
| Equity to Debt Ratio Past Year | 0.67 |
| Equity to Debt Ratio Most Recent Quarter | 0.66 |
| Total Stockholder Equity Past Year | 778,348,000 |
| Total Stockholder Equity Prior Year | 870,130,000 |
| Total Stockholder Equity Most Recent Quarter | 727,214,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 124,204,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 3.02 |
| Free Cash Flow Past Year | 178,753,000 |
| Free Cash Flow Prior Year | 139,488,000 |
Options |
|
| Put/Call Ratio | 8.43 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 20.88 |
| 20-Day Bollinger Middle Band | 24.57 |
| 20-Day Bollinger Upper Band | 28.26 |
| Beta | 0.23 |
| RSI | 0.00 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 1/10/2026 5:40:49 AM EST |